Year None202120202019201820172016 Date Latest Press Release August 13, 2018 Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia August 10, 2018 Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results August 7, 2018 Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference August 6, 2018 Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health July 31, 2018 Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection June 4, 2018 Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ May 30, 2018 Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference May 24, 2018 Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock May 23, 2018 Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock May 16, 2018 Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
